A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...

CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven't experienced ...

Please provide your email address to receive an email when new articles are posted on . Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed ...

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Having a well-rounded care team can make large B-cell lymphoma treatment easier. Learn how nurses, social workers, and other ...

Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...